Aquestive Therapeutics to Present at Leerink Partners Forum
Event summary
- Aquestive Therapeutics will participate in the Leerink Partners Therapeutics Forum on July 14, 2026.
- The company will host 1x1 investor meetings during the event.
- Forum panels will focus on immunology/inflammation and metabolism therapeutic themes.
- Aquestive is advancing Anaphylm™ for anaphylaxis treatment and AQST-108 for dermatological conditions.
The big picture
Aquestive Therapeutics' participation in the Leerink Partners Forum highlights its focus on expanding investor awareness of its innovative drug delivery technologies. The company's dual role as a developer and contract manufacturer positions it uniquely in the competitive pharmaceutical landscape, particularly in specialty areas like allergy treatments and dermatology.
What we're watching
- Pipeline Progress
- How Anaphylm™ and AQST-108 clinical developments will impact Aquestive's market positioning.
- Investor Sentiment
- Whether the 1x1 investor meetings generate positive momentum for Aquestive's stock.
- Strategic Focus
- The pace at which Aquestive can balance proprietary product development with CDMO operations.
Related topics